Please ensure Javascript is enabled for purposes of website accessibility

3 Things to Consider Before You Buy Coronavirus Vaccine Stocks

By Adria Cimino - Updated Mar 7, 2021 at 9:56AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investing in vaccine stocks today is different than it was a year ago.

The coronavirus vaccine space is constantly changing. It began last year as high-risk. This year, companies have brought products to market. Risk has declined for those players and others that have successfully advanced candidates. In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss three important points to keep in mind before investing in today's coronavirus vaccine market.

Corinne Cardina: Adria, could you give us three takeaways for investors looking at the COVID vaccine stock landscape.

Adria Cimino: Sure. I would say we should focus now on companies that can best adapt to new strains. That's really a very important thing right now because these mutations causing new variants are not going to stop. And so that's a real key point to be looking at. My second takeaway: It's important to consider outside factors. Because even if a vaccine is great, if for instance, like the U.S. market right now where the government has ordered so many vaccine doses from Pfizer and Moderna. So it might make it difficult for others in the U.S. in the near term. So, to look at outside factors that might affect vaccine orders. Finally, if you want to invest in this space, continue to watch the leaders, but also some smaller players because they can be pretty innovative and come up with new things. One I wrote about not too long ago was Gritstone Oncology (GRTS -7.48%), which is working on a coronavirus vaccine but very early stage. There are some opportunities in early stage companies as well.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gritstone bio, Inc. Stock Quote
Gritstone bio, Inc.
GRTS
$1.98 (-7.48%) $0.16
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.40 (-1.83%) $0.94
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$137.71 (-3.21%) $-4.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.